Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Pathol Biol (Paris) ; 63(3): 136-43, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25845294

ABSTRACT

Hemolytic uremic syndrome is a rare disease, frequently responsible for renal insufficiency in children. Recent findings have led to renewed interest in this pathology. The discovery of new gene mutations in the atypical form of HUS and the experimental data suggesting the involvement of the complement pathway in the typical form, open new perspectives for treatment. This review summarizes the current state of knowledge on both typical and atypical hemolytic uremic syndrome pathophysiology and examines new perspectives for treatment.


Subject(s)
Hemolytic-Uremic Syndrome/physiopathology , Animals , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Bacterial Infections/complications , Bacterial Toxins/adverse effects , Clinical Trials as Topic , Complement System Proteins/physiology , Disease Models, Animal , Drug Evaluation, Preclinical , Escherichia coli Infections/complications , Escherichia coli Infections/microbiology , Forecasting , Genetic Predisposition to Disease , Hemolytic-Uremic Syndrome/classification , Hemolytic-Uremic Syndrome/etiology , Hemolytic-Uremic Syndrome/genetics , Hemolytic-Uremic Syndrome/microbiology , Hemolytic-Uremic Syndrome/therapy , Humans , Kidney Transplantation , Liver Transplantation , Mice , Papio , Plasma , Plasma Substitutes , Shiga Toxin/adverse effects , Shiga-Toxigenic Escherichia coli/immunology , Shiga-Toxigenic Escherichia coli/pathogenicity , Thrombophilia/etiology , Vascular Endothelial Growth Factor A/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL